Patients News | pharmaphorum

News

Lynparza gets OK for use in prostate, breast cancers on NHS

AstraZeneca and Merck & Co’s Lynparza will be made available to prostate and breast cancer patients in England and Wales, after cost-effectiveness assessor NICE backed

News

J&J raises talc offer to $9bn with new insolvency bid

Johnson & Johnson has made an offer of nearly $9 billion to try to resolve tens of thousands of lawsuits it faces in the US that claim its talc products cause cancer.&

News

Eisai plans ‘patient-proposed’ trial of cancer drug Tazverik

Eisai has reached an agreement with Japan’s National Cancer Centre to run a trial of its EZH2 inhibitor Tazverik in young people with cancers who either have no drug treatment availab

News

ABPI names new members of its patient advisory council

The Association of the British Pharmaceutical Industry (ABPI) has added five new patient organisation figures to its patient advisory council, set up to provide patient pe

News

J&J’s bankruptcy bid to resolve talc claims blocked

Johnson & Johnson’s attempt to draw a line under the ongoing litigation it faces over allegations that its talc products cause cancer has been blocked by an appeals co

News

Clinical trial go-between Inato raises $20m

Inato has raised $20 million in early-stage financing to support the continued development of its clinical trial marketplace, which connects sponsors with its network of t

Lynparza gets OK for use in prostate, breast cancers on NHS

J&J raises talc offer to $9bn with new insolvency bid

Eisai plans ‘patient-proposed’ trial of cancer drug Tazverik

ABPI names new members of its patient advisory council

J&J’s bankruptcy bid to resolve talc claims blocked

Clinical trial go-between Inato raises $20m

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks